Entity
  • Cellectis

    Created in 1999
  • BETA

    Trend leader (A+)
    Existing signals make this entity one of the most dynamic startups
  • Social networks

    4,549 43,278
  • Activities

  • Technologies

  • Entity types

  • Location

    8 Rue de la Croix Jarry, 75013 Paris, France

    Paris

    France

  • Employees

    Scale: 51-200

    Estimated: 232

  • SIREN

    428859052
  • Engaged corporates

    19
    6 8
  • Added in Motherbase

    5 years, 3 months ago
Description
  • Value proposition


    Cellectis is developing life-changing product candidates to target and eradicate cancer cells.


    Cellectis is a global clinical-stage biopharmaceutical company. Pioneers and innovators in our field, our mission is to develop innovative treatments for patients with unmet medical needs.

    With 25 years of expertise, we have the best-in-class gene editing platform focusing on immuno-oncology, and gene therapy. Through our efficient and precise TALEN® technology, we create allogeneic CAR-T cells capable of recognizing and combating cancer cells.

    Today, our two* clinical programs target patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL).

    We are fully integrated and a leader in end-to-end gene editing, allogeneic CAR T-cell companies. With our in-house manufacturing, we control our gene and cell therapy process from start to finish with starting materials produced in Paris (France) and CAR-T therapy products created in Raleigh, NC (USA).

    We also have several ongoing strong collaborations, based on our TALEN® technology, with leading cell & gene therapy companies, including our recent partnership with AstraZeneca, to develop new product candidates in oncology, immunology, and treatment of rare diseases.

    At Cellectis, we are committed to a cure.

    Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

    To find out more about us, visit our website: www.cellectis.com. To learn more about our community guidelines, visit: http://www.cellectis.com/en/social-media-guidelines/

    Follow our other social media accounts: @cellectis on LinkedIn on X (formerly Twitter) .

    (*) On November 4, 2024, Cellectis decided to focus its current development efforts on the BALLI-01 and NATHALI-01 studies and therefore to deprioritize the development of UCART123.

    TALEN® is a registered trademark owned by the Cellectis Group.

    Gene editing, Life sciences, Oncology, T-Cell therapies, genome engineering, allogeneic, and off-the-shef CART therapies

  • Original language


    Cellectis is developing life-changing product candidates to target and eradicate cancer cells.


    Cellectis is a global clinical-stage biopharmaceutical company. Pioneers and innovators in our field, our mission is to develop innovative treatments for patients with unmet medical needs.

    With 25 years of expertise, we have the best-in-class gene editing platform focusing on immuno-oncology, and gene therapy. Through our efficient and precise TALEN® technology, we create allogeneic CAR-T cells capable of recognizing and combating cancer cells.

    Today, our two* clinical programs target patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL).

    We are fully integrated and a leader in end-to-end gene editing, allogeneic CAR T-cell companies. With our in-house manufacturing, we control our gene and cell therapy process from start to finish with starting materials produced in Paris (France) and CAR-T therapy products created in Raleigh, NC (USA).

    We also have several ongoing strong collaborations, based on our TALEN® technology, with leading cell & gene therapy companies, including our recent partnership with AstraZeneca, to develop new product candidates in oncology, immunology, and treatment of rare diseases.

    At Cellectis, we are committed to a cure.

    Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

    To find out more about us, visit our website: www.cellectis.com. To learn more about our community guidelines, visit: http://www.cellectis.com/en/social-media-guidelines/

    Follow our other social media accounts: @cellectis on LinkedIn on X (formerly Twitter) .

    (*) On November 4, 2024, Cellectis decided to focus its current development efforts on the BALLI-01 and NATHALI-01 studies and therefore to deprioritize the development of UCART123.

    TALEN® is a registered trademark owned by the Cellectis Group.

  • Home | Cellectis

    Cellectis is a clinical-stage biopharmaceutical company developing the Next-Generation CAR T-Cells to Cure Cancer

  • https://www.cellectis.com/
Corporate interactions BETA
Corporate TypeTweets Articles
Orange
Orange
Telecoms, Law Practice, Telecommunications
Orange
Telecoms, Law Practice, Telecommunications
Other

27 Feb 2020


La Tribune
La Tribune
Media, Newspapers
La Tribune
Media, Newspapers
Other

27 Jun 2022


Centre-Val de Loire Region
Centre-Val de Loire Region
National and local authorities, Government Administration
Centre-Val de Loire Region
National and local authorities, Government Administration
Other

13 Dec 2019


Illumina For Startups
Illumina For Startups
Startup accelerator & VC, Biotechnology, Biotechnology Research
Illumina For Startups
Startup accelerator & VC, Biotechnology, Biotechnology Research
Other

26 Jun 2015


Greater Paris University Hospitals - AP-HP
Greater Paris University Hospitals - AP-HP
Health, Hospitals and Health Care
Greater Paris University Hospitals - AP-HP
Health, Hospitals and Health Care
Other

27 Feb 2020


Biogen
Biogen
Biotechnology, Biotechnology Research
Biogen
Biotechnology, Biotechnology Research
Other

13 Apr 2021


Merck Group
Merck Group
Pharmaceutical, Biotechnology, Pharmaceutical Manufacturing
Merck Group
Pharmaceutical, Biotechnology, Pharmaceutical Manufacturing
Other

12 Dec 2019


AstraZeneca
AstraZeneca
Pharmaceutical, Pharmaceutical Manufacturing
AstraZeneca
Pharmaceutical, Pharmaceutical Manufacturing
Other

9 Nov 2017

9 May 2024



Catapult.org
Catapult.org
National and local authorities, Civic & Social Organization
Catapult.org
National and local authorities, Civic & Social Organization
Other

11 Feb 2019


Nasdaq
Nasdaq
Finance, Financial Services
Nasdaq
Finance, Financial Services
Other

29 Jul 2016


Similar entities
Loading...
Loading...
Social network dynamics